These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 22371220)
1. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Balak DM; Hengstman GJ; Çakmak A; Thio HB Mult Scler; 2012 Dec; 18(12):1705-17. PubMed ID: 22371220 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. Balak DM; Hengstman GJ; Hajdarbegovic E; van den Brule RJ; Hupperts RM; Thio HB BMC Neurol; 2013 Oct; 13():146. PubMed ID: 24131589 [TBL] [Abstract][Full Text] [Related]
3. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)]. Federal service on surveillance in healthcare and social development (Roszdravnadzor) Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163 [No Abstract] [Full Text] [Related]
4. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
5. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related]
7. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738 [TBL] [Abstract][Full Text] [Related]
12. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies. Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307 [TBL] [Abstract][Full Text] [Related]
13. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA; Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268 [TBL] [Abstract][Full Text] [Related]
14. Systematic review of depression in patients with multiple sclerosis and its relationship to interferonβ treatment. Alba Palé L; León Caballero J; Samsó Buxareu B; Salgado Serrano P; Pérez Solà V Mult Scler Relat Disord; 2017 Oct; 17():138-143. PubMed ID: 29055445 [TBL] [Abstract][Full Text] [Related]
15. [Disease modifying drugs in multiple sclerosis and pregnancy]. Tur C; Tintoré M; Aguilera C Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277 [No Abstract] [Full Text] [Related]
17. [A possible effect of the immunomodulating therapy with beta-interferons and glatimer acetate on the development of thyroid disease in patients with multiple sclerosis]. Petrova LV; Boĭkova AN; Batysheva TT; Gusev EI Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):58-67. PubMed ID: 21916158 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Mahurkar S; Suppiah V; O'Doherty C Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284 [TBL] [Abstract][Full Text] [Related]
19. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Devonshire V; Lapierre Y; Macdonell R; Ramo-Tello C; Patti F; Fontoura P; Suchet L; Hyde R; Balla I; Frohman EM; Kieseier BC; Eur J Neurol; 2011 Jan; 18(1):69-77. PubMed ID: 20561039 [TBL] [Abstract][Full Text] [Related]
20. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]